

**IN THE CLAIMS**

Please amend the claims as follows:


1. (Currently amended) A composition comprising a TNP-470 conjugated to a polymer, wherein the polymer is water soluble and has a molecular weight not greater than 60 kDa, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
2. (Canceled)
3. (Original) The composition of claim 1, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
4. (Canceled)
5. (Original) The composition of claim 1, further comprising a peptide linker between the TNP-470 and the polymer.
6. (Original) The composition of claim 1, further comprising a targeting ligand.



angiogenic disease is a solid tumor, a lymphoma, a leukemia, diabetic retinopathy or macular degeneration.

9. (Canceled)
10. (Previously presented) A method for decreasing neurotoxicity of TNP-470, comprising conjugating the TNP-470 to a polymer, wherein the polymer is water soluble and has a molecular weight not greater than 60 kDa.
11. (Canceled)
12. (Previously presented) The method of claim 10, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
13. (Original) The method of claim 10, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
14. (Original) The method of claim 10, further comprising a peptide linker between the antiangiogenic agent and the polymer.





Wherein wherein x is 90-95 and y is 5-10.